Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Patients With Relapsed/Refractory Marginal Zone Lymphoma

NCT07638722 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT07638722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07638722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MOZART MZL: A Randomized Phase II Study Evaluating Mosunetuzumab Alone and in Combination With Either Zanubrutinib or Polatuzumab Vedotin for the Treatment of Patients With Relapsed/Refractory Marginal Zone Lymphoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 3, 2026
Completion date
April 3, 2035
Enrollment
138 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, recurrent nodal marginal zone lymphoma, recurrent splenic marginal zone lymphoma, refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, refractory nodal marginal zone lymphoma, refractory splenic marginal zone lymphoma